ASH 2025: Interpreting Rapid Change Across Hematology
Returning from the American Society of Hematology Annual Meeting in Orlando, one message was clear:...
Posts about
Clinical Trial Regulations (2)
Monthly FDA Guidance and Regulatory News Review - November 2025
November brought significant FDA activity, with new final and draft guidances—from Pre-RFD updates...
Monthly FDA Guidance and Regulatory News Review - October 2025
Each month, Veristat's regulatory team tracks and shares a selection of new Regulatory Guidance...
Monthly FDA Guidance and Regulatory News Review - September 2025
Each month, Veristat's regulatory team tracks and shares a selection of new Regulatory Guidance...
Monthly FDA Guidance and Regulatory News Review - August 2025
Each month, Veristat's regulatory team tracks and shares a selection of new Regulatory Guidance...
IND Success Strategy: Building a High-Quality IND from Scratch with Strategic Gap Analysis
Learn how our regulatory affairs team was able to work with a sponsor to build a complete,...
Monthly FDA Guidance and Regulatory News Review - July 2025
Each month, Veristat's regulatory team tracks and shares a selection of new Regulatory Guidance...
NDA Success Strategy: Using Non-US Clinical Data in an NDA Submission
When our sponsor acquired an investigational asset from an international company, they faced a...
On Track and in Sync: How Veristat Continues to Support Efficient FDA Interactions
In today’s regulatory climate, ongoing discussion about FDA workload, funding constraints, and...
FDA’s Project FrontRunner: A Path Forward for Cancer Drug Development
The FDA’s Oncology Center of Excellence (OCE) is shifting the paradigm in cancer treatment...